In conclusion, STAT3 mutations cause DNA hypermethylation resulting in sensitivity to DNMT inhibitors, which could be considered as a novel treatment option for LGLL patients with resistance to standard treatments. The gene discussed is STAT3; the disease is T-cell large granular lymphocyte leukemia.